Changes in Renal Function by Nebulized Colistimethate Treatment
Korean Journal of Clinical Pharmacy
;
: 92-98, 2017.
Artigo
em Coreano
| WPRIM
| ID: wpr-120976
ABSTRACT
BACKGROUND:
Nebulized colistimethate is increasingly used, because there are problems such as renal dysfunction and low distribution within the lungs when colistimethate is administered intravenously. This study was designed to compare and analyze the changes in renal function by of nebulized colistimethate treatment for its safe administration.METHODS:
This study retrospectively reviewed the electronic medical records of adult patients above 19 years old, receiving only the nebulized colistimethate at least 4 days in Yonsei university health system from Nov 2014 to Aug 2015. Acute kidney injury (AKI) was determined by using the RIFLE criteria (Risk, Injury, Failure, Loss and End-stage renal disease) according to serum creatinine (SCr) levels before and after use of nebulized colistimethate.RESULTS:
48 patients were included our study and their SCr increased significantly after nebulized colistimethate treatment (SCr₀ vs. SCr₁; 0.85±0.80 vs. 1.00±0.82 mg/dL, n=48, p0.05). The study has a significance in that it reviewed the safety of nebulized colistimethate only treatment to national patients, analyzing its nephrotoxicity. It has confirmed that nebulized colistimethate is a safer method than intravenous injection, and requires to establish a guideline for the use of nebulized colistimethate in further studies with broader patient groups. (a) SCr Male 0.68-1.19 mg/dL, Female 0.49-0.91 mg/dL
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Valores de Referência
/
Estudos Retrospectivos
/
Creatinina
/
Registros Eletrônicos de Saúde
/
Injúria Renal Aguda
/
Injeções Intravenosas
/
Pulmão
/
Métodos
Tipo de estudo:
Guia de Prática Clínica
/
Estudo observacional
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Korean Journal of Clinical Pharmacy
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS